Tests BEY1107 with temozolomide in people with recurrent glioblastoma
Tests BEY1107 plus temozolomide in adults whose glioblastoma has returned or worsened.
Key facts
- Who runs it
- BeyondBio Inc.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Started
- 29 Nov 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Treatments tested
- BEY1107
- Temozolomide
- Record updated
- 10 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose glioblastoma has come back or grown after the first standard treatment. It tests BEY1107 together with temozolomide.
- Age
- 19 years or older.
- Sex
- Men and women can join.
- Disease stage
- Glioblastoma (GBM) confirmed on tissue examination, which has come back or progressed, with no response to the first standard treatment. At least 1 lesion that can be measured or evaluated by RANO criteria.
- Earlier treatment
- Must have had the first standard treatment. Cannot have had chemotherapy for recurrent GBM after that. Cannot have had another investigational drug within 4 weeks before screening. If taking corticosteroids, the dose must be stable, with no increase in the 2 weeks before the study drug.
Main reasons for not taking part
- Chemotherapy for recurrent GBM after the first standard treatment
- Another cancer in the past (some exceptions apply, such as treated basal cell skin cancer)
- Active hepatitis B, hepatitis C, or HIV positive
- Heart or blood vessel disease at screening
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Adult males and females aged over 19 years or older at the time of Informed Consent
- Diagnosed with GBM according to the World Health Organization(WHO) criteria
- Subjects with progression or recurrence, with no response to the initial standard of care after being confirmed as GBM on histopathology
- Subjects with 1 or more lesions that are measurable or evaluable according to the Response Assessment in Neuro-Oncology(RANO) criteria
- Subjects with European Cooperative Oncology Group(ECOG) performance status 0 or 1
- For Subjects using corticosteroids, those who do not need escalation within at least 2 weeks prior to administration of Investigational Product(IP) and on a stable dose
- Women of childbearing potential who are not surgically sterile must consent to practice acceptable contraception until 6 months after the end of IP administration and also have the evidence of not being fertile; 8 Non-vasectomized men who consent to use an acceptable contraception by one-self and the partner until 3 months after the end of IP administration
- Subjects who are fully informed of this trial, voluntarily decide to participate in the trial and provide written consent to comply with requirements for the trial
Who cannot take part
- Subjects who have not recovered from the toxicity of the prior anticancer therapy
- Subjects who had a major surgery requiring general anesthesia within 4 weeks of screening
- Subjects with hypersensitivity to the ingredient(s) or excipient(s) of the investigational product (BEY1107) or temozolomide
- Subjects who take a Rifampin, Phenytoin and azole class antifungal drugs in combination
- Subjects who had been administered other IP within 4 weeks prior to screening
- Patients with a history of chemotherapy for treatment of recurrent glioblastoma multiforme after the initial standard of care as of screening
- Subjects who have past history of major gastrointestinal surgery making oral drug administration impossible or possibly affecting absorption of IP
- Subjects with a history of other malignancy except adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ, papillary thyroid cancer or early gastric cancer
- Subjects with hypersensitivity to dacarbazine (DTIC)
- Subjects who have the cardiovascular disease as of screening
- Active hepatitis B, C or HIV positive
- Patients with acute or severe infection
- Subjects with a genetic problem(eg. Galactose intolerance)
- Patients with inadequate bone marrow, kidney and liver function
- Pregnant women, breastfeeding women, or positive findings on the pregnancy test at screening
- Subjects with life expectancy of less than 12 weeks by the investigator
- Subjects determined by the investigator to be ineligible for participation in this trial
Where in South Korea
- Seoul National University HospitalSeoul, South KoreaContact: Beyondbio Inc.Taking people
About the trial
What the trial wants to find out
This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
The group in the trial
- BEY1107 + TemozolomideTreatment being tested
Administer BEY1107 in combination with Temozolomide, 4-weeks as 1 cycle.
Treatment: BEY1107 and Temozolomide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-label, Phase I Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patient with Recurrent or Progressive Glioblastoma Multiforme (GBM)
- Plain-language title
- Tests BEY1107 with temozolomide in people with recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 March 2025